SCHEMBL3469757

SCHEMBL3469757

Cc1cc(O)cc(C)c1CO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.48
CHRM1 P11229 1/20 0.48
ALOX15 P16050 1/20 0.48
MAOA P21397 1/20 0.48
TBXA2R P21731 1/20 0.48
ADRA1A P35348 1/20 0.48
HTR2B P41595 1/20 0.48
ACHE P22303 2/20 0.43
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.38
HSP90AA1 P07900 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
BACE1 P56817 1/20 0.37
APP P05067 1/20 0.37
MAOB P27338 1/20 0.37
SHBG P04278 1/20 0.37
ESR2 Q92731 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22089476 0.84 CYP3A4 (0.39) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL22089477 0.84 CYP3A4 (0.50) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL29970906 0.84 CYP3A4 (0.50) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL29971161 0.84 CYP3A4 (0.39) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL18073446 0.82 CYP3A4 (0.38) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL95192 0.80 HRH3 (0.40) ACHEALDH1A1TDP1KDM4EGAA
SCHEMBL892872 0.80 CA1 (0.48) CYP3A4ALDH1A1SHBGSMN1; SMN2TDP1
SCHEMBL675857 0.80 CYP3A4 (0.50) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL22095632 0.79 CYP3A4 (0.35) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL6285400 0.78 CYP3A4 (0.48) CYP3A4CHRM1ALOX15MAOATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378268-B2 Heterocyclic THR-β receptor agonist compound and preparation method and use therefor Hepagene Therapeutics (HK) Limited (CN) 2025-08-05 US disclosed
US-20230416460-A1 COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED PRODUCT, AND LAMINATED SUBSTRATE TDK CORPORATION (JP) 2023-12-28 US disclosed
US-11827596-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-11-28 US disclosed
CN-116490355-A Compound, resin composition, resin sheet, resin cured product, and laminated substrate TDK株式会社 2023-07-25 CN disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 US disclosed
WO-2022209495-A1 COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED OBJECT, AND LAMINATED SUBSTRATE TDK株式会社 2022-10-06 WO disclosed
US-20220298187-A1 HETEROCYCLIC THR-B RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREFOR HEPAGENE THERAPEUTICS HK LTD (CN) 2022-09-22 US disclosed
CN-112457346-B Fused-ring THR beta receptor agonist compound and preparation method and application thereof 和博医药有限公司 2022-09-06 CN disclosed
EP-4019524-A1 HETEROCYCLIC THR-BETA RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREFOR Hepagene Therapeutics (HK) Limited (HK) 2022-06-29 EP disclosed
US-10420781-B2 Thyroid hormone receptor agonist and use thereof METABASIS THERAPEUTICS INC. (US) 2019-09-24 US disclosed
US-7202359-B2 Azaoxa heterocyclic compound and method of preparing the same CHANG CHUN PLASTICS CO., LTD. (TW) 2007-04-10 US disclosed
CN-1234706-C Nitrogen-oxygen heterocyclic compound and preparation method thereof CHANGCHUN ARTIFICIAL RESIN FAC (CN) 2006-01-04 CN disclosed
US-20050085634-A1 Azaoxa heterocyclic compound and method of preparing the same CHANG CHUN PLASTICS CO., LTD. (TW) 2005-04-21 US disclosed
CN-1490318-A Nitrogen-oxygen heterocyclic compound and preparation method thereof 长春人造树脂厂股份有限公司 2004-04-21 CN disclosed
US-20040068084-A1 Azaoxa heterocyclic compound and method of preparing the same CHANG CHUN PLASTICS CO., LTD. (TW) 2004-04-08 US disclosed
US-6211328-B1 IN PRESENCE OF AN ACID GUN EI CHEMICAL INDUSTRY CO., LTD (JP) 2001-04-03 US disclosed
US-4233431-A HEAT AND CHEMICAL RESISTANT STABILIZERS-POLYCARBONATE BAYER AKTIENGESELLSCHAFT (DE) 1980-11-11 US disclosed
US-4142035-A Polycondensates containing hydroxyquinoline end groups, their use for the preparation of polymers containing metals and metal containing polycondensates BAYER AKTIENGESELLSCHAFT (DE) 1979-02-27 US disclosed
US-4137219-A STABILIZERS BAYER AKTIENGESELLSCHAFT (DE) 1979-01-30 US disclosed
US-3983160-A Process for the preparation of hydroxyphenylacetonitriles BAYER AKTIENGESELLSCHAFT (DT) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068084-A1 Azaoxa heterocyclic compound and method of preparing the same AOX1, KDM1A, BMI1 CYP3A4 1456/4885CHRM1 2049/4885ALOX15 228/4885
US-11667606-B2 Thyromimetics TPO, TSHR, TTR CYP3A4 918/4885CHRM1 5/4885ALOX15 1864/4885
US-10420781-B2 Thyroid hormone receptor agonist and use thereof THRB, THRA, TSHR CYP3A4 1018/4885CHRM1 911/4885ALOX15 2864/4885
US-12378268-B2 Heterocyclic THR-β receptor agonist compound and preparation method and use therefor THRB, THRA, ADRB1 CYP3A4 1105/4885CHRM1 543/4885ALOX15 2319/4885
US-20050085634-A1 Azaoxa heterocyclic compound and method of preparing the same AOX1, KDM1A, BMI1 CYP3A4 1249/4885CHRM1 2316/4885ALOX15 219/4885
US-20220298187-A1 HETEROCYCLIC THR-B RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREFOR THRB, THRA, TRHR CYP3A4 1334/4885CHRM1 806/4885ALOX15 2304/4885
US-11827596-B2 Thyromimetics TPO, TSHR, TTR CYP3A4 918/4885CHRM1 8/4885ALOX15 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.